Answers are grounded in this paper and cite their sources.
Demonstrates improved therapeutic efficacy in BNCT with modified boron liposomes, indicating enhanced cellular interactions.
Efficient delivery of boron is a critical determinant of the therapeutic efficacy of boron neutron capture therapy (BNCT). However, conventional boron-loaded liposomal systems often suffer from low encapsulation efficiency (EE), resulting in a significant loss of costly 10 B-enriched compounds and limited practical applicability. In this study, we established a remote loading strategy for the efficient encapsulation of boron compounds into liposomes. By employing a transmembrane ion gradient, boron-encapsulated liposomes (BLPs) were prepared with an encapsulation efficiency of 42.1% and a boron-to-phospholipid ( B / P ) ratio of 2, demonstrating the feasibility of remote loading for boron delivery. To further enhance liposome–cell interactions, BLPs were modified with cancer cell membrane interfaces derived from MDA-MB-231 cells. The resulting CM-BLPs exhibited significantly enhanced cellular association, achieving a boron accumulation of 125 ng[B]/10 6 cells, and showed stable retention without detectable leakage under physiological conditions. In vitro BNCT irradiation experiments revealed that CM-BLPs exhibited greater therapeutic efficacy than both unmodified BLPs and 4-borono- l -phenylalanine (BPA). These results demonstrate the feasibility of remote loading as a practical and scalable strategy for boron delivery in BNCT with cell membrane interfaces serving as a complementary approach to enhance cellular interactions.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: